Vaccination against herpes zoster in developed countries

References

• Hope-Simpson RE. The Nature of Herpes Zoster: a Long-Term Study and a New Hypothesis. Proc R Soc Med 1965; 58:9 - 20; PMID: 14267505
   PubMedGoogle Scholar
• Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med 1983; 309:1434 - 40; http://dx.doi.org/10.1056/NEJM198312083092306; PMID: 6195526
   PubMed Web of Science ®Google Scholar
• Gnann JW Jr., Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340 - 6; http://dx.doi.org/10.1056/NEJMcp013211; PMID: 12151472
   PubMed Web of Science ®Google Scholar
• Head H, Campbell AW, Kennedy PG. The pathology of Herpes Zoster and its bearing on sensory localisation. Rev Med Virol 1997; 7:131 - 43; http://dx.doi.org/10.1002/(SICI)1099-1654(199709)7:3<131::AID-RMV198>3.0.CO;2-7; PMID: 10398478
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67:241 - 51; http://dx.doi.org/10.1016/0304-3959(96)03122-3; PMID: 8951917
   PubMed Web of Science ®Google Scholar
• Oxman MN. Clinical manifestation of herpes zoster. In Arvin AM, Gerson AA, eds. Varicella zoster virus: virology and clinical management. Cambridge, England: Cambridge University press. 246-275., 2000.
   Google Scholar
• Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5:344 - 56; http://dx.doi.org/10.1016/j.jpain.2004.06.001; PMID: 15336639
   PubMed Web of Science ®Google Scholar
• Johnson RW, Wasner G, Saddier P, Baron R. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008; 25:991 - 1006; http://dx.doi.org/10.2165/0002512-200825120-00002; PMID: 19021299
   PubMed Web of Science ®Google Scholar
• Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; CD006866; PMID: 19370655
   PubMed Web of Science ®Google Scholar
• Bruxelle J, Pinchinat S. Effectiveness of antiviral treatment on acute phase of herpes zoster and development of post herpetic neuralgia: review of international publications. Med Mal Infect 2012; 42:53 - 8; http://dx.doi.org/10.1016/j.medmal.2011.11.001; PMID: 22169279
   PubMed Web of Science ®Google Scholar
• Mick G, Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster--a review. Curr Med Res Opin 2012; 28:937 - 51; http://dx.doi.org/10.1185/03007995.2012.690339; PMID: 22551228
   PubMed Web of Science ®Google Scholar
• Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P Jr., Rauck R, et al, NGX-4010 C116 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008; 7:1106 - 12; http://dx.doi.org/10.1016/S1474-4422(08)70228-X; PMID: 18977178
   PubMed Web of Science ®Google Scholar
• Irving G, Backonja M, Rauck R, Webster LR, Tobias JK, Vanhove GF. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain 2012; 28:101 - 7; http://dx.doi.org/10.1097/AJP.0b013e318227403d; PMID: 21753727
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al, Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271 - 84; http://dx.doi.org/10.1056/NEJMoa051016; PMID: 15930418
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19:3076 - 90; http://dx.doi.org/10.1016/S0264-410X(01)00044-5; PMID: 11312002
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127:305 - 14; http://dx.doi.org/10.1017/S0950268801005921; PMID: 11693508
   PubMed Web of Science ®Google Scholar
• De Moragas JM, Kierland RR. The outcome of patients with herpes zoster. AMA Arch Derm 1957; 75:193 - 6; http://dx.doi.org/10.1001/archderm.1957.01550140037006; PMID: 13393787
   PubMedGoogle Scholar
• Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25:571 - 5; PMID: 1195231
   PubMedGoogle Scholar
• Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010; 11:1211 - 21; http://dx.doi.org/10.1016/j.jpain.2010.02.020; PMID: 20434957
   PubMed Web of Science ®Google Scholar
• Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007; 132:Suppl 1 S52 - 9; http://dx.doi.org/10.1016/j.pain.2007.02.004; PMID: 17379412
   PubMedGoogle Scholar
• Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341 - 9; http://dx.doi.org/10.4065/82.11.1341; PMID: 17976353
   PubMed Web of Science ®Google Scholar
• Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011; 52:332 - 40; http://dx.doi.org/10.1093/cid/ciq077; PMID: 21217180
   PubMed Web of Science ®Google Scholar
• Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005; 133:245 - 53; http://dx.doi.org/10.1017/S095026880400281X; PMID: 15816149
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44:Suppl 1 S1 - 26; http://dx.doi.org/10.1086/510206; PMID: 17143845
   PubMed Web of Science ®Google Scholar
• Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20:2500 - 7; http://dx.doi.org/10.1016/S0264-410X(02)00180-9; PMID: 12057605
   PubMed Web of Science ®Google Scholar
• Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360:678 - 82; http://dx.doi.org/10.1016/S0140-6736(02)09837-9; PMID: 12241874
   PubMed Web of Science ®Google Scholar
• Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002 - 7; http://dx.doi.org/10.1086/430325; PMID: 15897984
   PubMed Web of Science ®Google Scholar
• Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005; 5:68; http://dx.doi.org/10.1186/1471-2458-5-68; PMID: 15960856
   PubMed Web of Science ®Google Scholar
• Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 2011; 29:8580 - 4; http://dx.doi.org/10.1016/j.vaccine.2011.09.024; PMID: 21939721
   PubMed Web of Science ®Google Scholar
• Haanpää M, Laippala P, Nurmikko T. Pain and somatosensory dysfunction in acute herpes zoster. Clin J Pain 1999; 15:78 - 84; http://dx.doi.org/10.1097/00002508-199906000-00003; PMID: 10382920
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Nagasako EM, Johnson RW, Griffin DR. Acute pain in herpes zoster: the famciclovir database project. Pain 2001; 94:113 - 9; http://dx.doi.org/10.1016/S0304-3959(01)00347-5; PMID: 11576750
   PubMed Web of Science ®Google Scholar
• Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62:1545 - 51; http://dx.doi.org/10.1212/01.WNL.0000123261.00004.29; PMID: 15136679
   PubMed Web of Science ®Google Scholar
• Benbernou A, Drolet M, Levin MJ, Schmader KE, Oxman MN, Johnson R, et al. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain 2011; 15:1100 - 6; http://dx.doi.org/10.1016/j.ejpain.2011.04.014; PMID: 21600819
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Gnann JW Jr., Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008; 9:Suppl 1 S37 - 44; http://dx.doi.org/10.1016/j.jpain.2007.10.008; PMID: 18166464
   PubMed Web of Science ®Google Scholar
• Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007; 11:Suppl 2 S43 - 8; http://dx.doi.org/10.1016/S1201-9712(07)60021-6; PMID: 18162246
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010; 26:656 - 66; PMID: 20842005
   PubMed Web of Science ®Google Scholar
• Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546 - 53; http://dx.doi.org/10.1128/AAC.39.7.1546; PMID: 7492102
   PubMed Web of Science ®Google Scholar
• Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9:863 - 9; http://dx.doi.org/10.1001/archfami.9.9.863; PMID: 11031393
   PubMedGoogle Scholar
• Opstelten W. Herpes zoster and postherpetic neuralgia in general practice. The Netherland: Utrecht University, 2005:186.
   Google Scholar
• Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23:490 - 6; http://dx.doi.org/10.1097/AJP.0b013e318065b6c9; PMID: 17575488
   PubMed Web of Science ®Google Scholar
• Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39:342 - 8; http://dx.doi.org/10.1086/421942; PMID: 15307000
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010; 182:1731 - 6; http://dx.doi.org/10.1503/cmaj.091711; PMID: 20921251
   PubMed Web of Science ®Google Scholar
• Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010; 8:37; http://dx.doi.org/10.1186/1741-7015-8-37; PMID: 20565946
   PubMed Web of Science ®Google Scholar
• Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006; 24:1308 - 14; http://dx.doi.org/10.1016/j.vaccine.2005.09.026; PMID: 16352376
   PubMed Web of Science ®Google Scholar
• Singhal PK, Makin C, Pellissier J, Sy L, White R, Saddier P. Work and productivity loss related to herpes zoster. J Med Econ 2011; 14:639 - 45; http://dx.doi.org/10.3111/13696998.2011.607482; PMID: 21838599
   PubMedGoogle Scholar
• White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009; 27:781 - 92; http://dx.doi.org/10.2165/11317560-000000000-00000; PMID: 19757871
   PubMed Web of Science ®Google Scholar
• Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine 2012; 30:2047 - 50; http://dx.doi.org/10.1016/j.vaccine.2012.01.045; PMID: 22285632
   PubMed Web of Science ®Google Scholar
• Aronsson G, Gustafsson K, Dallner M. Sick but yet at work. An empirical study of sickness presenteeism. J Epidemiol Community Health 2000; 54:502 - 9; http://dx.doi.org/10.1136/jech.54.7.502; PMID: 10846192
   PubMed Web of Science ®Google Scholar
• Prochaska JO, Evers KE, Johnson JL, Castle PH, Prochaska JM, Sears LE, et al. The well-being assessment for productivity: a well-being approach to presenteeism. J Occup Environ Med 2011; 53:735 - 42; http://dx.doi.org/10.1097/JOM.0b013e318222af48; PMID: 21691220
   PubMed Web of Science ®Google Scholar
• Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000; 321:794 - 6; http://dx.doi.org/10.1136/bmj.321.7264.794; PMID: 11009518
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Weiss HL, Soong SJ, Gnann JW. Herpes zoster: risk categories for persistent pain. J Infect Dis 1999; 179:9 - 15; http://dx.doi.org/10.1086/314562; PMID: 9841816
   PubMed Web of Science ®Google Scholar
• Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002; 19:471 - 5; http://dx.doi.org/10.1093/fampra/19.5.471; PMID: 12356697
   PubMed Web of Science ®Google Scholar
• Coen PG, Scott F, Leedham-Green M, Nia T, Jamil A, Johnson RW, et al. Predicting and preventing post-herpetic neuralgia: are current risk factors useful in clinical practice?. Eur J Pain 2006; 10:695 - 700; http://dx.doi.org/10.1016/j.ejpain.2005.11.002; PMID: 16427792
   PubMed Web of Science ®Google Scholar
• Volpi A, Gatti A, Pica F, Bellino S, Marsella LT, Sabato AF. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 2008; 80:1646 - 52; http://dx.doi.org/10.1002/jmv.21254; PMID: 18649332
   PubMed Web of Science ®Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18:350 - 4; http://dx.doi.org/10.1097/00002508-200211000-00002; PMID: 12441828
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C, et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 2012; 153:342 - 9; http://dx.doi.org/10.1016/j.pain.2011.10.026; PMID: 22138256
   PubMed Web of Science ®Google Scholar
• Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, comparative review and user Guide. 2007.
   Google Scholar
• Szende A, Williams A. Measuring self-reported population health: An international perspective based on EQ-5D. 2007.
   Google Scholar
• van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27:1454 - 67; http://dx.doi.org/10.1016/j.vaccine.2008.12.024; PMID: 19135492
   PubMed Web of Science ®Google Scholar
• Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008; 4:238 - 45; http://dx.doi.org/10.4161/hv.4.3.5686; PMID: 18382137
   PubMed Web of Science ®Google Scholar
• Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine 2012; 30:675 - 84; http://dx.doi.org/10.1016/j.vaccine.2011.10.036; PMID: 22120193
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr., McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922 - 8; http://dx.doi.org/10.1093/cid/cir970; PMID: 22291101
   PubMed Web of Science ®Google Scholar
• Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis 2007; 45:1527 - 9; http://dx.doi.org/10.1086/523011; PMID: 17990240
   PubMed Web of Science ®Google Scholar
• Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, et al, Shingles Prevention Study Group. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc 2010; 58:1634 - 41; http://dx.doi.org/10.1111/j.1532-5415.2010.03021.x; PMID: 20863322
   PubMed Web of Science ®Google Scholar
• Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al, Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320 - 8; http://dx.doi.org/10.1093/cid/cis638; PMID: 22828595
   PubMed Web of Science ®Google Scholar
• Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?. Vaccine 2012; 30:2795 - 800; http://dx.doi.org/10.1016/j.vaccine.2011.09.079; PMID: 21964056
   PubMed Web of Science ®Google Scholar
• Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145:317 - 25; PMID: 16954357
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44:1280 - 8; http://dx.doi.org/10.1086/514342; PMID: 17443464
   PubMed Web of Science ®Google Scholar
• Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25:8326 - 37; http://dx.doi.org/10.1016/j.vaccine.2007.09.066; PMID: 17980938
   PubMed Web of Science ®Google Scholar
• Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009; 27:991 - 1004; http://dx.doi.org/10.2165/11314010-000000000-00000; PMID: 19908924
   PubMed Web of Science ®Google Scholar
• Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc 2010; 8:7; http://dx.doi.org/10.1186/1478-7547-8-7; PMID: 20433704
   PubMedGoogle Scholar
• Annemans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ 2010; 13:537 - 51; http://dx.doi.org/10.3111/13696998.2010.502854; PMID: 20707768
   PubMedGoogle Scholar
• van Hoek AJ, Melegaro A, Gay N, Bilcke J, Edmunds WJ. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine 2012; 30:1225 - 34; http://dx.doi.org/10.1016/j.vaccine.2011.11.026; PMID: 22119592
   PubMed Web of Science ®Google Scholar
• van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res 2010; 10:237; http://dx.doi.org/10.1186/1472-6963-10-237; PMID: 20707884
   PubMed Web of Science ®Google Scholar
• Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007; 25:155 - 69; http://dx.doi.org/10.2165/00019053-200725020-00007; PMID: 17249857
   PubMed Web of Science ®Google Scholar